NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance).
Galanis E, Anderson S, Butowski N, Hormigo A, Schiff D, Tran D, Omuro A, Jaeckle K, Kumar S, Kaufmann T, Buckner J, Twohy E, Giannini C, Wen P. NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance). Journal Of Clinical Oncology 2017, 35: 2023-2023. DOI: 10.1200/jco.2017.35.15_suppl.2023.Peer-Reviewed Original ResearchProgression-free survivalII trialMedian progression-free survivalRandomized phase II trialPhase II trialGlioma stem cellsOverall survivalOverall incidenceRecurrent glioblastomaMultiple time pointsVEGF inhibitionGrade 3GBM patientsPositive subsetSingle agentI cohortResponse rateHumanized antibodyFlow cytometryEndothelial cellsTime pointsTGFβ receptorsGlioblastomaBevacizumabCD105